Enovis ENOV Surgical — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Enovis in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Enovis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enovis's surgical — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Enovis's surgical — net sales?
- Enovis (ENOV) reported surgical — net sales of $317.13M in Q1 2026.
- How has Enovis's surgical — net sales changed year-over-year?
- Enovis's surgical — net sales increased by 10.8% year-over-year, from $286.25M to $317.13M.
- What is the long-term trend for Enovis's surgical — net sales?
- Over 4 years (2021 to 2025), Enovis's surgical — net sales has grown at a 29.1% compound annual growth rate (CAGR), from $400.16M to $1.11B.
- What does surgical — net sales mean?
- This metric represents the total revenue generated from the sale of products and services within the company's surgical division after deducting returns, allowances, and discounts. It serves as a primary indicator of market demand and the commercial success of the company's reconstructive and surgical medical device portfolio. Tracking this figure allows investors to assess the growth trajectory and competitive positioning of the surgical business unit relative to broader market trends.